Ex-GSK chief Andrew Witty summoned back to the frontlines of vaccine development at embattled WHO

Amber Tong

During his 10-year tenure at GlaxoSmithKline, Andrew Witty made vaccines one of his signature areas of focus, leading the pharma giant to an approval for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex-GSK chief Andrew Witty summoned back to the frontlines of vaccine development at embattled WHO

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bristol Myers prunes pipeline amid new round of cost cuts

Pfizer hires Novartis oncology exec to steer its cancer ambitions

AstraZeneca takes $753M charge on abandoned complement drug from Alexion deal

Bristol Myers launches fresh round of major cost cuts in bid to get ahead of patent cliff

Updated: Lilly posts 45% sales jump, culls four programs across obesity, Alzheimer's, heart failure and eczema

J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

Ex-GSK chief An­drew Wit­ty sum­moned back to the front­lines of vac­cine de­vel­op­ment at em­bat­tled WHO

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Ex-GSK chief Andrew Witty summoned back to the frontlines of vaccine development at embattled WHO